Cure8 research brief
This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when IV steroids fail.
Adults with severe UC not responding to IV steroids, gastroenterologists managing ASUC, IBD researchers, and clinicians considering non‑biologic rescue options.
This multicenter retrospective study from India looked at tofacitinib (a JAK inhibitor) as second-line therapy for biologic‑naive patients with steroid‑refractory acute severe ulcerative colitis (ASUC). The abstract reports rapid clinical responses in most patients within 7–10 days and steroid‑free clinical remission rates above 60% at 24 weeks.
Adverse events occurred in a minority (17%), including cases of tuberculosis and herpes zoster; a few patients required temporary or permanent drug discontinuation. The authors conclude tofacitinib appears promising as rescue therapy after IV steroid failure but note the need for randomized trials.
This summary is based on the article abstract provided by the journal; Cure8 has not reviewed any full published paper beyond that abstract.
This is a retrospective, nonrandomized multicenter study (abstract). Results are encouraging but not definitive; randomized controlled trials are needed to confirm safety and effectiveness. The abstract reports infectious adverse events including tuberculosis and herpes zoster.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
A natural compound (diosgenin) reduced disease signs and inflammatory markers in a mouse model of ulcerative colitis, suggesting a possible anti-inflammatory mechanism that could inform future preclinical research.
Pregnancy planning and contraception are important for people with IBD because active disease at conception is linked to worse pregnancy outcomes. The article shows many women with IBD are unsure about how contraception...
